Neuland Lab commissions its first peptide manufacturing module
A new peptide manufacturing module comes online, adding capacity for peptide production.
Source →The trace
How it reaches your house.
Starting from PolyPeptide Group (Recipharm), we walked the supply graph hop by hop to the goods you buy and the companies you own. Each step is the engine’s reasoning, scored for confidence and cited where a source backs it.
First impact
AmbioPharm Inc. →supply upGLP-1 Receptor Agonist Peptide API (Semaglutide / Liraglutide Type)
Neuland’s first commercial peptide module adds 7,000L of reactor capacity, which should ease supply for peptide APIs; AmbioPharm’s 3% market share and non-sole-supplier status suggest a moderate market effect.
57% confidencePolyPeptide Group (Recipharm) →supply upGLP-1 Receptor Agonist Peptide API (Semaglutide / Liraglutide Type)
Neuland’s new peptide module adds manufacturing capacity, so this peptide API market should become more available; the effect is modest because PolyPeptide’s listed share is only 5% and the source does not specify this exact GLP-1 output.
47% confidenceCordenPharma International →supply upGLP-1 Receptor Agonist Peptide API (Semaglutide / Liraglutide Type)
Hop 2
GLP-1 Receptor Agonist Peptide API (Semaglutide / Liraglutide Type) →supply upGLP-1 drugs (Ozempic, Wegovy, Mounjaro)
Added peptide-module capacity should increase GLP-1 peptide API availability, easing the critical input bottleneck for these drugs.
91% confidenceHop 3
GLP-1 drugs (Ozempic, Wegovy, Mounjaro) →supply upGLP-1 Receptor Agonist Peptide API (Semaglutide / Liraglutide Type)
A new peptide manufacturing module should raise output and availability of the GLP-1 receptor agonist API that is a critical input for this drug basket.
82% confidence
Where it lands
What you buy, and what you own.
Goods you buy
GLP-1 drugs (Ozempic, Wegovy, Mounjaro)
Companies you may own
No named companies on this path.
Tap a company to see what it told the SEC could break it.
In the MyPRIA app, this is checked against your own holdings.